This speculative small-cap biotech play may be something to keep an eye on as it trades for around $3 per share. Or, with its other in-progress immuno-oncology candidates. Even so, there’s big potential for it to strike success with Balstilimab. This may signal it will have to replenish its current cash reserves (around $119 million) with new capital, most likely from dilutive stock offerings. The company is burning through cash ($45 million in the most recent quarter). Other candidates in its pipeline, like its cancer therapies AGEN1181 and AGEN1777, show strong promise as well. But, this isn’t the company’s sole catalyst. This is following positive results from a recent clinical trial. Yet, this could reverse, given the possible catalyst in its flagship candidate, Balstilimab.Ī therapy for recurrent/metastatic cervical cancer, the company has recently submitted Balstilimab for accelerated Food and Drug Administration (FDA) approval.
At recent prices (about $3.13 per share), they are slightly down year-to-date. Shares have not only given up their gains. But, rallying from around $3.25 per share at the start of 2021, to around $5.20 per share in early February, some nimble traders likely pocketed fast profits.īut, as hype around small-cap stocks has taken a breather, so has interest in AGEN stock. It may not have been a “to the moon” moment for the stock. So, which small-cap stocks in the biotech space could make game-changing moves in the near future? These seven, although still risky bets, may break out once again:Īn immuno-oncology play, Agenus shares were flying high at the peak of the meme stock/Reddit stock phenomenon. 7 Stocks to Start Your Robinhood Portfolio With Just $2,000.But, they too could see big boosts if their drug candidates make progress in clinical trials. That is, candidates that could either vaccinate against, or treat, the novel coronavirus. Yet, in the vast field of biotech names, there are a few strong opportunities. With the hype still fading, they face continued moves lower, as the meme stock crowd chases after crypto instead.
For some plays, unfortunately, that’s not going to be the case. For these kinds of high-risk plays to see big moves, they need to wow investors with game-changing catalysts. Earlier this year, speculators on platforms like Reddit’s r/WallStreetBets sent scores of small biotech stocks “to the moon” on little more than hype.īut, now, online chatter isn’t enough anymore. That’s been especially the case for speculative biotech plays. Ever since “meme stock madness” screeched to a halt, small-cap stocks have been in a slump.
0 kommentar(er)
